For the first time in more than twenty years, doctors have a genuinely new kind of painkiller to work with — and it doesn't come with the shadow that has followed opioids for a generation.
The drug is called suzetrigine, sold under the brand name Journavx, and it was approved by the US Food and Drug Administration in January 2025 as the first in an entirely new class of pain medicines. A year on, the clinical data is maturing, prescriptions are spreading, and UK pain specialists are watching closely.
The promise is simple, even if the chemistry is not: relief comparable to a low-dose opioid for moderate to severe acute pain, but with no addiction risk, no drowsiness and no respiratory depression.
How it works
Most painkillers either dull pain at the site of injury, like ibuprofen, or act on the brain, like opioids. Suzetrigine does something different. It works on the nerves themselves — the wiring that carries the pain signal from, say, a surgical wound up toward the spinal cord and brain.
Those nerves rely on tiny gateways called sodium channels to fire off their electrical messages. Suzetrigine selectively blocks one particular gateway, NaV1.8, which is found almost exclusively in peripheral pain-sensing neurons. It is, in effect, a mute button for one specific channel of the body's pain broadcast — leaving the heart, brain and other tissues untouched.
The drug's developer, Vertex Pharmaceuticals, reports more than 31,000-fold selectivity for that pain pathway. In plain English: it is astonishingly precise.
Why it matters
The context is sobering. Nearly 727,000 people died from opioid overdoses in the United States between 1999 and 2022, according to the Centers for Disease Control and Prevention. The UK has been spared the worst of the American crisis, but prescription opioid use has climbed steadily for years, and overdose deaths in Scotland remain among the highest in Europe.
The problem has never been that opioids don't work. They work extraordinarily well. The problem is that they work on the brain's reward system at the same time as its pain system, and for some people that combination is devastating.
"For pain physicians, the holy grail of medication management is something that can block pain with no side effects," Dr Robert Chow, a pain specialist at Yale Medicine, told Yale News earlier this year. "The ideal scenario is one that works as well as opioids, but without the untoward side effects."
The UK picture
Suzetrigine is not yet licensed in the UK, and the Medicines and Healthcare products Regulatory Agency has not announced a decision. But a recent review in the British Journal of Anaesthesia described it as "a notable pharmacological advance," and GSK is among several pharmaceutical companies developing their own NaV1.8 inhibitors — meaning a whole family of drugs, rather than a single product, could eventually arrive in British hospitals.
For now, clinical trials have focused on short-term, post-surgical pain — tummy tucks, bunion removals and similar procedures. Suzetrigine matched the opioid Vicodin for relief in those studies, with side effects largely limited to itching, muscle spasms and rash.
It is not a cure-all. Early results in sciatica were disappointing, and the drug is not yet approved for chronic pain. The list price in the US — around £12 a tablet, with two a day typical — is also considerably higher than a generic opioid.
A first step, not the last
Professor Stephen Waxman, the Yale neuroscientist whose laboratory first identified NaV1.8's role in pain signalling more than 25 years ago, has called the drug's approval a "proof of concept" rather than a finished answer.
"This is a first step," he said. "We have more work to do, but I expect that next-generation drugs will be even better."
For the millions of people who will have surgery this year, and for those who have watched loved ones caught in the grip of opioid dependence, that first step is worth celebrating.
